Amanta Healthcare

Amanta Healthcare Limited IPO

MAINBOARD

Amanta Healthcare IPO Details

Open Date
01 Sep 2025
Close Date
03 Sep 2025
Listing Date
08 Sep 2025
Issue Price
₹120 - ₹126
Face Value
₹10 per share
Lot Size
119
GMP
₹22 (17.5%)
Issue Type
IPO
Listing On
NSE, BSE
Type
Book Built Issue
Share holding pre issue
28829351
Share holding post issue
-
Total Issue Size
1,00,00,000 shares (aggregating up to ₹126.00 Cr)
Fresh Issue
1,00,00,000 shares (aggregating up to ₹126.00 Cr)
Offer for Sale
-

Amanta Healthcare IPO Dates

  • 01 Sep 2025
    Opening dateOPD
  • 03 Sep 2025
    Closing dateCOD
  • 04 Sep 2025
    Basis of AllotmentBOA
  • 05 Sep 2025
    Initiation of RefundsIOR
  • 05 Sep 2025
    Credit of SharesCOS
  • 08 Sep 2025
    Listing dateLID

Amanta Healthcare IPO Lot Size

ApplicationLotsSharesAmount
Retain Minimum1119₹14,994
Retain Maximum131547₹194,922
SHNI Minimum141666₹209,916
SHNI Maximum667854₹989,604
BHNI Minimum677973₹1,004,598

Amanta Healthcare IPO Reservation

Promoter Holding

Pre Issue:85.60%
Post Issue:63.56%
Promoter Names:
Bhavesh Patel, Vishal Patel, Jayshreeben Patel, Jitendra Kumar Patel, Milcent Appliances Private Limited.

Amanta Healthcare IPO Valuations

ROE:12.42%
ROCE:13.72%
DEBT/EQUITY:2.02
RONW:10.89%
PAT MARGIN:3.86%

Amanta Healthcare Limited Financial Information

Period Ended31 Mar 202531 Mar 202431 Mar 2023
Assets381.76352.12374.06
Total Income276.09281.61262.70
Profit After Tax10.503.63-2.11
EBITDA61.0558.7656.31
Net Worth96.3966.2962.88
Reserves and Surplus67.5639.4636.05
Total Borrowing195.00205.23215.66
Amount in ₹ Crore

About Amanta Healthcare IPO

Incorporated in December 1994, Amanta Healthcare Limited is a pharmaceutical company that specializes in the development, manufacturing, and marketing of a diverse array of sterile liquid products, specifically parenteral products, which are packaged in plastic containers utilizing Aseptic Blow-Fill-Seal (“ABFS”) and Injection Stretch Blow Moulding (“ISBM”) technologies. The company is also a manufacturer of medical devices.

The company manufactures fluid therapy formulations, including IV fluids, diluents, ophthalmic solutions, and respiratory care products. It also offers irrigation solutions, first-aid products, and eye lubricants in the medical device segment.

The company markets products through three business units:

  1. National sales,
  2. International sales and
  3. Product partnering with various foreign and Indian pharmaceutical companies.

The company manufactures over 45 generic products, marketing them under their brands in India through 320 distributors and stockists.

The company sells products in Africa, Latin America, the UK, and beyond. Its products are registered in 19 countries and comply with various regulations. In Fiscal 2025, the company exported branded products to 21 countries.

As of March 31, 2025, the company has a team of 1,718 employees at its formulation and development and quality laboratory.

 

Strength Of Amanta Healthcare IPO

1. Well established manufacturer of pharmaceutical formulations with diverse product portfolio and diverse market.

2. Large manufacturing capabilities.

3. Wide Domestic and International Marketing Network.

4. Experienced management team supported by large, diverse and skilled work force.

Risk Of Amanta Healthcare IPO

1. Our Company's entire manufacturing facility is located at a single location, and all of the Company's manufactured products are produced from such facility in village Hariyala, district Kheda, Gujarat. Any delay in production at, or shutdown of, our manufacturing facility due to various factors such as shortage of electrical power or water resources, political instability, industrial accidents or machinery breakdowns, severe weather conditions, natural disasters, and outbreak of infectious diseases may in turn adversely affect our business, financial condition and results of operations.

2. Any manufacturing or quality control concerns or our inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by our clients and distributors, which could have an adverse effect on our business, results of operations, financial condition and cash flows.

3. Our Company is involved in a certain material litigation and an adverse outcome in this proceeding may adversely affect our business, financial condition and growth strategy.

4. We may not be able to improve our profit margins and profits in the future.

5. Our Company had issued Equity Shares to more than 49 investors in the past and as a matter of abundant caution for better corporate governance, our Company has given an exit offer to the eligible shareholders.

6. Finance cost of the Company has been very high and finance cost of the company for the Fiscal 2025, Fiscal 2024, and Fiscal 2023 constituted 45.78%, 57.25% and 62.64% of the Restated Earnings before interest, tax, depreciation and amortization (EBITDA). If company is unable to control the finance cost in future, it may adversely affect business, results of operations, financial condition and cash flows.

7. Our operations are labour intensive, and we may be subject to strikes, work stoppages or increased wage demands by our employees, increase in minimum wages across various states and we may also be unable to engage new employees at commercially attractive terms which could adversely affect our business, results of operations and financial condition.

8. We rely on limited suppliers for our raw material i.e., LDPE (Low Density Polyethylene) and PP granules (Polypropylene). The prices of LDPE and PP granules are volatile and largely linked to crude price volatility. Loss of these suppliers, or any fluctuation in the prices of these raw materials may have an adverse effect on our business, results of operations and financial conditions.

9. The Issue Price, market capitalisation to revenue multiple and price to earnings ratio of our Company based on the Issue Price may not be indicative of the market price of our Company on listing or thereafter or indicative of such multiples and ratios based on the market price of the Equity Shares on listing or thereafter.

10. Our manufacturing license has been suspended in the past and any such suspensions in the future could adversely affect our business, results of operations, financial condition and cash flows.

Objectives Amanta Healthcare IPO

  1. Funding capital expenditure requirements for civil construction work and towards the purchase of equipment, plant and machinery for setting up a new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat;
  2. Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up a new manufacturing line for SVP at Hariyala, Kheda, Gujarat; and
  3. General corporate purposes.

Company Contact Details

Amanta Healthcare Limited
8th Floor, Shaligram Corporates
C.J. Marg
Ambli,
Ahmedabad, Gujarat, 380058
Phone: 079 67777600
Email: cs@amanta.co.in
Website: https://www.amanta.co.in/

Registrar Contact Details

Name: MUFG Intime India Private Limited
Phone: +91-22-4918 6270

Comments